Psychedelics

Wednesday Jul 21, 2021 - 1:27 pm

InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Moving Psychedelic Therapeutics Field Forward Through Partnership

Cybin (NEO: CYBN) (OTCQB: CLXPF), a life sciences company advancing psychedelic therapeutics for various psychiatric and neurological conditions, is sponsoring research to see if psychedelic medicine, when used with EMBARK’s supportive therapy, can help clinicians recover from COVID-related distress. The recently launched EMBARK is a groundbreaking psychotherapy model that integrates leading clinical approaches to promote supportive healing with psychedelic medicine. Cybin has co-sponsored the study…

Wednesday Jul 21, 2021 - 10:02 am

InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF), University of Michigan to Collaborate in Phase 2a Clinical Trial for Fibromyalgia

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs through accelerated regulatory pathways, today announced its plans to conduct a phase 2a clinical trial with the Chronic Pain & Fatigue Research Center in the Department of Anesthesiology at the University of Michigan Medical School. According to the update, the open-label trial will evaluate the…

Tuesday Jul 13, 2021 - 1:16 pm

InvestorNewsBreaks – XPhyto Therapeutics Corp.’s (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Covid-ID Lab Filling Existing Market Gap

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience technology accelerator, recently announced that its distribution, storage and logistics partner, Max Pharma GmbH, began selling and delivering its 25-minute COVID-19 RT-PCR test system (“Covid-ID Lab”) in Germany on May 25. The company is likely to benefit from the country’s regulatory requirements and the government’s initiative that qualifies every resident to at least one free…

Tuesday Jul 13, 2021 - 9:36 am

InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Files Patent as Part of Digital Therapeutics Strategy

Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, has filed a new provisional patent application to protect its proprietary digital therapeutics platform; the patent is the company’s 13th. In addition, the company is also advancing the build-out of its digital therapeutics strategy, with the objective of evolving its programs beyond the psychedelic molecule into an eco-system with potential to improve…

Wednesday Jul 07, 2021 - 1:27 pm

InvestorNewsBreaks – Numinus Wellness Inc. (TSX.V: NUMI) Announces Plans to Combine Expertise, Create Centre for Excellence in Psychedelic Neurology

Numinus Wellness (TSX.V: NUMI), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced that it has agreed to acquire the Neurology Centre of Toronto ("NCT") pursuant to a purchase agreement dated July 2, 2021. According to the update, Numinus and NCT founder Dr. Evan Lewis plan to expand NCT into a comprehensive clinical neurology treatment centre with a unique…

Wednesday Jul 07, 2021 - 9:50 am

InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Announces Strategic Collaboration with the University of Michigan

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs through accelerated regulatory pathways, today announced an agreement with the University of Michigan to perform research related to Tryp's Psilocybin-for-Neuropsychiatric Disorders (“PFN(TM)”) program. According to the update, the collaboration is part of a series of upcoming bridging studies designed to expand Tryp's intellectual property portfolio…

Tuesday Jul 06, 2021 - 10:01 am

InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Announces Agreement with US Mental Health Chain Group

Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, has entered into an exclusive research and development collaboration agreement with TMS NeuroHealth Centers Inc. (“TMS”). TMS is a wholly owned subsidiary of Greenbrook TMS Inc. (TSX: GTMS) (NASDAQ: GBNH), a group of 129 outpatient mental health service centers located across the United States. According to the announcement, Cybin and Greenbrook will…

Tuesday Jun 29, 2021 - 11:49 am

InvestorNewsBreaks – Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) Announces Purchase Order from British Columbia Liquor Distribution Branch

Pure Extracts Technologies (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ), a plant-based extraction company focused on cannabis, hemp, functional mushrooms and the rapidly emerging psychedelic sector, has received an initial purchase order (“PO”) for its proprietary cannabis vape cartridges through its wholly owned subsidiary Pure Extracts Manufacturing Corp. The PO, which is an initial order for the company’s 1-gram, full-spectrum oil (“FSO”), cannabis vape cartridges, was…

Friday Jun 25, 2021 - 9:51 am

InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) to Participate in Fireside Chat at Grizzle Psychedelics Con

Cybin (NEO: CYBN) (OTCQB: CLXPF) is a leading biotechnology company focused on progressing psychedelic therapeutics. The company has announced that its Chief Executive Officer Doug Drysdale will participate in a virtual fireside chat at Grizzle Psychedelics Con on June 28, 2021. The fireside chat is slated to begin at 12:30 p.m. ET and will be webcast live at https://ibn.fm/Ec3zS with an archived version available after…

Thursday Jun 24, 2021 - 1:19 pm

InvestorNewsBreaks – Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) Enters Medicinal Cannabis Space Through Strategic Agreement

Pure Extracts Technologies (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ), a plant-based extraction company focused on cannabis, hemp, functional mushrooms and the rapidly emerging psychedelic sector, together with Canada House Wellness Group (CSE: CHV), a fully integrated medical cannabis company, have entered into a medical supply agreement. Under the agreement, Canada House’s wholly owned subsidiary, Abba Medix Corp., will purchase Pure Extracts’ full line of concentrate…

Thursday Jun 24, 2021 - 9:59 am

InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) to Take Virtual Stage at Psych Investor Summit

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing compounds for diseases with unmet medical needs, today announced that it is presenting at the Psych Investor Summit: Research & Development. The conference is slated to take place virtually on July 7. Tryp’s chairman and CEO Greg McKee will present information on the company and its drug development pipeline, with his presentation scheduled…

Thursday Jun 24, 2021 - 9:43 am

InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Names Former FDA Psychiatry Division Director to Clinical Advisory Board

Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, announced its newest Clinical Advisory Board member: Dr. Thomas Laughren. A former director for the Division of Psychiatry Products, Center for Drug Evaluation and Research at the FDA, Laughren oversaw the review of all psychiatric drug-development activities conducted under Investigational New Drug (“IND”) as well as the review of all New Drug…

Wednesday Jun 23, 2021 - 12:09 pm

InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Announces Participation at Life Sciences Investor Forum

Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, will be participating in the upcoming Life Sciences Investor Forum, scheduled for June 24, 2021. During the presentation, Cybin’s CEO Doug Drysdale will provide an overview of the company, including key information targeting the forum audience. Drysdale’s presentation is scheduled for 9 a.m. ET; an archived version of the presentation will be…

Tuesday Jun 22, 2021 - 1:19 pm

InvestorNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Advancing Rotigotine Development Program for Parkinson’s

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience technology accelerator, recently announced its drug formulation and development, conducted primarily by its wholly owned German subsidiary, Vektor Pharma TF GmbH, are on schedule and continue to expand in scope. A recent article reads, “A Q1 trial announced in January 2021 and focusing on a human bioavailability pilot study of the Rotigotine transdermal patch for…

Monday Jun 21, 2021 - 11:13 am

InvestorNewsBreaks – Psychedelic Capital: June 2021 to Feature Top Companies, Newest Opportunities, Deep Industry Insights

Microdose Psychedelic Insights, a cutting-edge media company focused on providing content, analysis and engaging events designed to drive the psychedelics industry to the forefront of modern medicine, will be hosting the upcoming Psychedelic Capital: June 2021. The conference is slated to take place in an entirely virtual format on June 30, 2021. The event will feature some of the top companies, latest IPOs, newest opportunities,…

Thursday Jun 17, 2021 - 10:02 am

InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) CEO Featured Guest in Latest Stock2Me Podcast

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing clinical-stage compounds for diseases with unmet medical needs, announced that chairman and CEO Greg McKee was interviewed on the most recent episode of the Stock2Me Podcast. The podcast features a fascinating array of companies and individuals that are actively revolutionizing business practices within their respective markets. In the interview, McKee talked about the…

Tuesday Jun 15, 2021 - 2:17 pm

InvestorNewsBreaks – Pure Extracts Technologies Corp.’s (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) BC Facility Ready to Meet Increasing Demand

Pure Extracts Technologies (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) is seeing interest from producers and brands looking for new opportunities and partnerships. In a corporate update focused on three points of interest in its growing business — cannabis, functional mushrooms and psilocybin — CEO Ben Nikolaevsky noted that the company’s Pemberton, British Columbia facility is fully operational and ready to meet the increasing demand for…

Tuesday Jun 15, 2021 - 2:00 pm

InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Collaborating to Create Safer, More Effective Protocol in ‘Fast-Moving Arena of Psychedelic Therapies’

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) is collaborating with psychedelic therapy educational platform Fluence to provide design and training for the psychotherapeutic portion of its Phase 2a clinical trials for treating eating disorders and fibromyalgia. “Fluence is led by researchers and psychotherapists with direct experience in conducting psychedelic clinical trials and is the foremost provider of psychotherapeutic training for health professionals that are administering psychedelic…

Monday Jun 14, 2021 - 1:08 pm

InvestorNewsBreaks – Microdose Psychedelic Insights’ Upcoming Event to Showcase the Potential of MDMA Therapeutics

Microdose Psychedelic Insights is a cutting-edge conference production company focused around promoting content, financial analysis and engaging events designed to drive the psychedelics industry into the forefront of modern medicine. In partnership with Pharmala Biotech Inc and ACS Pharmacology & Translational Science, Microdose Psychedelic Insights will host the upcoming MDMA Conference: A Molecular Masterclass in an entirely virtual format on June 15, 2021. The event…

Friday Jun 11, 2021 - 3:15 pm

InvestorNewsBreaks – InvestorBrandNetwork, PsychedelicNewsWire to Collaborate with Microdose Psychedelic Insights for Upcoming Standout Events

InvestorBrandNetwork (“IBN”), a multifaceted financial news and publishing company, today announced that it, together with its PsychedelicNewsWire (“PNW”) brand, will be collaborating with Microdose Psychedelic Insights for upcoming June conferences. The events slated for later this month include the MDMA Conference, set to be held on June 15, 2021, as well as the Psychedelic Capital Conference, taking place on June 30, 2021. The virtual MDMA…

Thursday Jun 10, 2021 - 2:08 pm

InvestorNewsBreaks – Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) Eyes Exciting Month in Commencement of Production, Sales of CBD Gummies

Pure Extracts Technologies (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ), a plant-based extraction company focused on cannabis, hemp, functional mushrooms and the rapidly emerging psychedelic sector, is pleased to announce that its wholly owned subsidiary, Pure Extracts Manufacturing Corp., has developed and is in production of innovative, high potency CBD edible gummies for the Canadian market. “June is going to be a very exciting month for…

Tuesday Jun 08, 2021 - 10:07 am

InvestorNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Issues Update on Timely Progression of Psychedelic Medicine Program

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) today announced that its GMP mescaline synthesis program is on schedule with the completion of initial production batches. According to the update, the industrial-scale manufacture of pharmaceutical-grade psychedelic compounds, including mescaline and psilocybin, is an important part of XPhyto's psychedelic medicine program and will provide a foundation for its drug formulation and clinical validation work. “With both…

Thursday Jun 03, 2021 - 9:45 am

InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) to Participate at Upcoming LD Micro Invitational XI

Cybin (NEO: CYBN) (OTCQB: CLXPF) CEO Doug Drysdale will be participating at the 2021 LD Micro Invitational XI. The invitational will be held Thursday, June 10. As part of his participation, Drysdale will be presenting a live webcast featuring Cybin, a biotechnology company focused on progressing psychedelic therapeutics. Drysdale’s presentation is scheduled to begin at 3:30 p.m. ET. Interested individuals can register to view the…

Tuesday Jun 01, 2021 - 10:23 am

InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) to Sponsor Pioneering Study Designed to Expand Understanding of Psychedelic Pharmacotherapy

Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, today announced the sponsorship of Kernel’s feasibility study of its Kernel Flow technology to measure ketamine’s psychedelic effect on cerebral cortex hemodynamics. In January 2021, Cybin announced that it would be partnering with Kernel to leverage its proprietary Kernel Flow device for psychedelic-based studies and clinical trials. The first-of-its-kind Kernel Flow device…

Friday May 28, 2021 - 12:34 pm

InvestorNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Eyes Potential Expansion of ‘Covid-ID Lab’

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience technology accelerator, recently received the CE-IVD approval (European certification) of its 25-minute COVID-19 RT-PCR test kits (“Covid-ID Lab”). The approval facilitated initial sale and distribution of the Covid-ID Lab in Germany and, later, other parts of Europe, the Middle East and North America. The company also recently announced delivery of 2,000 units of Covid-ID Lab…

Thursday May 27, 2021 - 10:27 am

InvestorNewsBreaks – Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) Secures Purchase Order from British Columbia LDB

Pure Extracts Technologies (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ), a plant-based extraction company focused on cannabis, hemp and the rapidly emerging psychedelic sector, today announced that its wholly owned subsidiary, Pure Extracts Manufacturing Corp., through its distribution partner, has received an initial purchase order for its edible cannabis gummies from the British Columbia Liquor Distribution Branch (“LDB”). Demand for Pure Extracts’ Pure Chews branded THC…

Wednesday May 26, 2021 - 10:03 am

InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Announces PCT Filing, Bringing Potential to Obtain Patent Coverage in 153 Countries

Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, today announced that it has filed an international patent application that further strengthens its psychedelic derivative drug development candidates across 153 global jurisdictions. Per the update, the application, governed by the Patent Cooperation Treaty (“PCT”), grants Cybin the right to file future national applications into treaty member jurisdictions, including important potential markets…

Tuesday May 25, 2021 - 1:37 pm

InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Expands Team to Add Deep Clinical, Commercial and Regulatory Expertise

Cybin (NEO: CYBN) (OTCQB: CLXPF), a life sciences company advancing psychedelic therapeutics for various psychiatric and neurological conditions, recently appointed Alexander Belser as its chief clinical officer and Aaron Bartlone to serve as chief operating officer. Belser and Bartlone bring a wealth of experience and will provide the company with added insight and expertise in the expansion of its development and clinical operations in the…

Thursday May 20, 2021 - 12:17 pm

InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Leverages Key Initiatives to Advance Drug Candidates

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) is a pharmaceutical company focused on developing clinical-stage compounds for diseases with high unmet medical needs. “Tryp’s current focus is on advancing its two drug development platforms: its Psilocybin-for-Neuropsychiatric Disorders (‘PFN’(TM)) program targeting fibromyalgia, eating disorders and chronic pain conditions; and razoxane for soft tissue sarcomas,” reads a recent article regarding Tryp’s positioning. The piece also discusses the company’s…

Wednesday May 19, 2021 - 2:21 pm

InvestorNewsBreaks – Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) Poised to Meet Demands of ‘Cannabis 2.0’

Pure Extracts Technologies (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) is positioned in a market that is still relatively scant for certified extractors able to meet demand for concentrates from cannabis biomass. Having just achieved a milestone moment with commencement of production of 25,000 vape cartridges for the Canadian retail market, the company is set for opportunity amid “Cannabis 2.0,” a post-legalization era in Canada that…

Tuesday May 18, 2021 - 10:47 am

InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Secures IRB Approval to Commence Study of Psilocybin Formulation in Treatment of Major Depressive Disorder

Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, has announced that the Institutional Review Board ("IRB") at the University of the West Indies Hospital in Jamaica has granted approval to commence the study of its sublingual psilocybin formulation ("CYB001") in a Phase II clinical trial for patients suffering with major depressive disorder ("MDD"). Commencement of the trial is subject to…

Friday May 14, 2021 - 1:40 pm

InvestorNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Focuses ‘Covid-ID Lab’ Commercialization Strategy Initially on German Market

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience technology accelerator, recently entered a strategic distribution, storage and logistics agreement for its commercial 25-minute COVID-19 RT-PCR test system (“Covid-ID Lab”). In April, XPhyto announced its entry into the agreement with a full-fledged German pharmaceutical wholesaler and service provider. Under the agreement, the German partner will distribute, store and deliver Covid-ID Lab test kits to…

Thursday May 13, 2021 - 11:54 am

InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Collaborates to Potentially Develop New Therapy for Treatment-Resistant Psychiatric Disorders

Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company advancing psychedelic therapeutics for various psychiatric and neurological conditions, recently acquired Adelia Therapeutics, thereby adding CYB003 to its pipeline. It subsequently made an equally important move when it inked a drug-development agreement with Catalent Inc. (NYSE: CTLT), a leading global provider of advanced delivery technologies, development and manufacturing solutions for drugs, biologics, cell and gene therapies, and…

Tuesday May 11, 2021 - 9:20 am

InvestorNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) CEO Talks Business in Two Video Interviews

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) director and CEO Hugh Rogers was a featured guest on two different video interviews. In both interviews, Rogers shared key information and updates about XPhyto, a bioscience accelerator focused on next-generation drug delivery, diagnostic and new active pharmaceutical ingredient investment opportunities. During his InvestorIntel interview with host Peter Clausi, Rogers mentioned that the company had recently received European…

Monday May 10, 2021 - 1:12 pm

InvestorNewsBreaks – Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) Integrates Cutting-Edge Tech for Faster Throughput, Highest Quality

Pure Extracts Technologies (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) has ordered a state-of-the-art Cosolvent Injection System (“CIS”) from British Columbia-based Vitalis. The investment will make Pure Extracts one of the first companies in the world to receive the system, which will position it for many benefits. The CIS will be an add-on that enhances Vitalis carbon dioxide extraction systems that Pure Extracts already uses in…

Monday May 10, 2021 - 9:32 am

InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Enters Master Agreement with Leading CRO Clinlogix

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing clinical-stage compounds for diseases with unmet medical needs, has entered into a master service agreement with Clinlogix, a contract research organization (“CRO”). The agreement is a key step for initiating and supporting the clinical development of Tryp’s psilocybin-for-neuropsychiatric disorders, or PFN(TM) (“PFN”), program. Tryp noted that Clinlogix has global experience in providing CRO services…

Friday May 07, 2021 - 10:28 am

InvestorNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Launches ‘Covid-ID Lab’ POC Pilot Project in Germany

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) today announced its commencement of a pilot project with its rapid COVID-19 PCR test ("Covid-ID Lab") in a point-of-care ("POC") setting in Germany. Covid-ID Lab was recently approved in Europe and offers the accuracy of a PCR test in only 25 minutes. Validated work flows, including mobile collection and processing of patient samples, will be further optimized…

Thursday May 06, 2021 - 10:20 am

InvestorNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Featured on Gamechangers LIVE

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) was featured in a recent episode of Gamechangers LIVE, a podcast series that shines a spotlight on individuals who are gamechangers in their fields and shares perspective on their journeys, mindsets, struggles and successes in an effort to inspire and inform listeners. XPhyto Therapeutics’ CEO and Director, Hugh Rogers, joined the broadcast, hosted by Executive Coach and…

Monday May 03, 2021 - 3:22 pm

InvestorNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Eyes Significant Market Opportunity

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience technology accelerator, raised eyebrows when it announced that XPhyto Laboratories Inc., its Alberta subsidiary, added mescaline production to its psychedelic medicine development programs earlier this year (https://ibn.fm/cHwJi). Mescaline has begun attracting legislative attention, much like was the case with cannabis, which gained widening legalization as state after state approved varied uses of hemp and cannabis within…

Monday May 03, 2021 - 12:52 pm

InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Eyes Rapid Progress to Clinical Studies for Psychedelic Drug Candidates

Cybin (NEO: CYBN) (OTCQB: CLXPF), a life sciences company advancing psychedelic therapeutics for various psychiatric and neurological conditions, has completed key in-vitro and in-vivo research studies. The company recently announced completion of its 20th pre-clinical study and the progression of two psychedelic drug candidates: CYB003 and CYB004. According to Cybin, the studies were completed in record time, in part due to close collaboration with the…

InvestorNewsBreaks

NewsBreak Category: Psychedelics

Get Started with InvestorWire

Press Distribution

Explore Press Distribution Solutions

Discover Add-on Solutions